CXCR7与肿瘤的发生、发展  

CXCR7 in tumorigenesis and progression

作　　者：侯恺林[1] 郝旻罡[2] 薄隽杰[1] 王建华[2] 

机构地区：[1]上海交通大学医学院附属仁济医院泌尿外科,上海200025 [2]上海交通大学医学科学研究院,上海200025

出　　处：《癌症》2010年第4期505-508,共4页Chinese Journal of Cancer

基　　金：上海市自然基金(09ZR14180000);上海市教育委员会重点学科建设项目(J-50208)~~

摘　　要：趋化因子属于分泌型细胞因子超家族,最早被认为前炎症性细胞因子,用来调节细胞的转运与黏附。但现今,趋化因子逐渐引起研究者的兴趣,因为越来越多的证据表明它们在肿瘤的发生和发展中发挥重要作用。CXCR7作为七次跨膜G蛋白偶联CXC亚型趋化因子受体,最近被证实与趋化因子CXCL11(I-TAC)及CXCL12(SDF-1)有高亲和力。这篇综述中,我们将着重阐述目前对于CXCR7在肿瘤生物学过程中发挥的重要作用,涉及到肿瘤的生长、存活、黏附、侵袭、转移、血管形成及肿瘤发展等过程。目前看来,运用多肽、小分子蛋白、抗体或siRNA技术针对CXCR7的靶向措施在不久的将来有望成为肿瘤治疗的新途径。Chemokines,a family of small cytokines,were initially characterized as proinflammatory chemoattractant cytokines that regulated cell trafficking and adhesion. Today,attention focuses on chemokines because evidence shows that they play a critical role in tumor initiation,promotion,and progression. CXCR7,a seven-transmembrane G-protein-coupled CXC chemokine receptor,has recently been identified as binding with high affinity to chemokines CXCL11 （I-TAC） and CXCL12 （SDF-1）. In this review,we highlight the current knowledge about the role of CXCR7 in the biologic processes of cancer,including cancer growth,survival,adhesion,invasion,metastasis,angiogenesis,and progression. The use of peptides,small molecules,antibodies,or small interfering RNA to target CXCR7 shows promise as new potential avenues for the treatment of cancer.

关 键 词：CXCR7 趋化因子 肿瘤发生 发展 

分 类 号：R730.2[医药卫生—肿瘤]